ProChon and Savyon co-operate on bladder cancer kit:
This article was originally published in Clinica
Rehovat, Israel-based ProChon Biotech and clinical diagnosis tools company Savyon Diagnostics last week struck a deal to develop and manufacture a genetic kit for the diagnosis of bladder cancer mutations. Under the agreement, Ashdod-based Savyon will assume responsibility for prototype kit development and manufacturing whilst ProChon, a discoverer and developer of fibroblast growth-factor based therapeutics, will be responsible for clinical development and will retain exclusive worldwide commercial rights.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.